Longer durations of piperacillin/tazobactam treatment cause more prolonged alteration of colonization resistance in mice
PLOS One · 2026
DOI: 10.1371/journal.pone.0350031 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Bryan S Hausman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Penicillanic Acid, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Broad-spectrum antibiotics that are excreted into the intestinal tract disrupt microbiota that provide colonization resistance against healthcare-associated pathogens. Minimizing the duration of treatment is a core element of efforts to reduce the adverse effects of antibiotics, but limited information is available on whether this approach preserves colonization resistance. Here, we used a mouse model to examine the impact of 1, 3, 6, and 10-days of treatment with the broad-spectrum antibiotic piperacillin/tazobactam on colonization resistance against vancomycin-resistant Enterococcus faecium (VRE) and carbapenemase-producing Klebsiella pneumoniae at 6-, 10-, and 24-days post-treatment; colonization resistance against Clostridioides difficile was tested at 6 days post-treatment. Colonization resistance was not altered at these time points by 1 day of treatment, whereas 3, 6, and 10 days of treatment caused more prolonged microbiota disruption and altered colonization resistance extending to 6, 10, and 24 days, respectively. In contrast, 5 or 10 days of treatment with aztreonam, a narrow-spectrum antibiotic with no activity against anaerobes, did not alter colonization resistance. These findings provide support for efforts to minimize the duration of antibiotic therapy as longer durations of piperacillin/tazobactam treatment caused greater and more prolonged alteration of colonization resistance. Our results also highlight the potential for short courses of broad-spectrum antibiotics to alter colonization resistance and suggest that selection of antibiotics that cause less disruption of anaerobes may be useful to preserve colonization resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States of America.
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
- Lerner Research Institute/Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States of America.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
- Geriatric Research, Education, and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States of America.
ORCID-Profile: Samir Memic, Curtis J Donskey
Förderung
- U.S. Department of Veterans Affairs
Zitieren
APA
Hausman, B. S., Kaple, C. E., Cadnum, J. L., Memic, S., Sangwan, N., & Donskey, C. J. (2026). Longer durations of piperacillin/tazobactam treatment cause more prolonged alteration of colonization resistance in mice. PLOS One. https://doi.org/10.1371/journal.pone.0350031
Vancouver
Hausman BS, Kaple CE, Cadnum JL, Memic S, Sangwan N, Donskey CJ. Longer durations of piperacillin/tazobactam treatment cause more prolonged alteration of colonization resistance in mice. PLOS One. 2026. doi:10.1371/journal.pone.0350031
BibTeX
@article{Hausman2026,
author = {Hausman, Bryan S and Kaple, Claire E and Cadnum, Jennifer L and Memic, Samir and Sangwan, Naseer and Donskey, Curtis J},
title = {Longer durations of piperacillin/tazobactam treatment cause more prolonged alteration of colonization resistance in mice},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0350031}
}
EUVIMED